SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Set of diferent colored scissors vector. Scissor icon in cartoon and flat style. Open cutting or nippers. Vector illustration.
Job Trends
July Layoffs Skyrocket 487% YOY With Merck Cuts
The number of biopharma professionals let go has increased year over year for three straight months. In July, as many as 8,000 people lost or were projected to lose their jobs, due largely to news that Merck projects to cut roughly 6,000 employees as part of a multiyear process.
August 5, 2025
 · 
4 min read
 · 
Angela Gabriel
©Vertex Pharmaceuticals Incorporated. All Rights Reserved.
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
August 5, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Human head with puzzle pieces and doodles vector illustration. Human brain lacking a piece of puzzle. Concept of brain function, memory loss, disorder, dementia. Abstract human head profile
Neuroscience
Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial
Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that of its closest competitors.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Start of negative growth trend. Worsening forecast. Cessation of rise inertia, not enough power energy. The risk of recession and sliding into a crisis
Regulatory
Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
A stack of white envelopes with a red envelope on top. Blue background with copy space.
Regulatory
Scientists Behind Trial of Replimune’s Tumor Destroyer Protest FDA’s Rejection
In an open letter, 22 experts who designed and ran Replimune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined in the complete response letter for the melanoma candidate RP1.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
cartoon showing teamwork to build a bridge across a chasm
Gene therapy
Cracking the Commercial Code for Cell and Gene Therapies
From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to make CGTs commercially viable. But it is possible, experts agreed at a recent panel.
August 5, 2025
 · 
9 min read
 · 
Jef Akst
a robotic assembly line with vials
Opinion
Fixing CGT Manufacturing Requires Not Automation, but a Return to Basics
The primary focus in scaling up production should first be the adoption of lean manufacturing principles used in virtually every other industry.
August 5, 2025
 · 
5 min read
 · 
Josh Ludwig
An obstacle to achieving a goal. Concerns and issues. Break through the refusal barrier. Face problems and challenges.
Immuno-oncology
Top FDA Cancer Regulator Intervened To Reject Replimune’s Melanoma Drug
According to reporting from multiple outlets, Richard Pazdur, head of the Oncology Center of Excellence at CDER, opposed the consensus opinion of CBER staff to approve the drug. Replimune’s stock has dropped precipitously since the rejection.
August 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Biontech SE headquarters with company flags, German biotechnology company, BioNTech Manufacturing, development and production active immunotherapeutic agents in Mainz, Germany - September 7, 2024
Earnings
BioNTech Commits to Infectious Diseases Amid Questions Over Vaccine Demand
The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of around 20% but that pricing and Comirnaty’s market share will hold steady.
August 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS